Methadone Pharmacy Bill Divides Addiction Treatment Providers

For half a century, methadone for opioid use disorder has been available in the United States only through federally certified opioid treatment programs and approved providers.

A reintroduced bipartisan bill would change that, and the medication-assisted treatment field is not speaking with one voice about whether it should.

Behavioral Health Business reported in July that the Modernizing Opioid Treatment Access Act 2.0, or MOTAA 2.0, has split provider organizations that broadly agree on the value of medication for opioid use disorder but disagree sharply on where that medication should be dispensed and by whom.

What the Bill Would Change

Senators Edward Markey of Massachusetts and Rand Paul of Kentucky reintroduced the legislation in June. An earlier version, introduced in 2023, did not pass.

The new version would allow board-certified addiction physicians to prescribe methadone and community pharmacies to dispense it. It also gives the Department of Health and Human Services authority to designate additional qualified prescribers beyond opioid treatment program clinicians and board-certified addiction specialists, without requiring further action from Congress.

The 2.0 version is narrower in several respects than its predecessor. It requires electronic prescribing, mandates reporting to state prescription drug monitoring programs, adds more granular enforcement data, and places oversight and reporting responsibilities with the Drug Enforcement Administration.

Supporters point to the access problem the bill is designed to solve. Under existing rules, many patients must appear at a clinic daily or every other day for a dose, which can mean long travel or missed medication for people without reliable transportation.

Understanding Methadone in Opioid Detox and Maintenance

Methadone is a long-acting full opioid agonist. In supervised withdrawal management it blunts cravings and suppresses acute withdrawal symptoms, which allows a person to stabilize rather than cycle through repeated withdrawal.

In maintenance treatment it is taken daily over a longer period, and it is one of two medications, alongside buprenorphine, that clinical guidelines treat as first-line care for opioid use disorder.

Because methadone is dosed to opioid tolerance, induction is the highest-risk window. Doses that are appropriate for a tolerant patient can be dangerous for someone whose tolerance has dropped, which is one reason the medication has historically been administered under direct observation.

Where Medication-Assisted Treatment Providers Disagree

Mark Dunn, director of public policy at the National Association of Addiction Treatment Providers, told Behavioral Health Business that access to appropriate medication has become an essential part of substance use disorder treatment, provided the prescriber is trained and the psychosocial side of treatment is not dropped.

He also noted that cost estimates for the bill have not historically accounted for offsetting savings elsewhere in health care, such as fewer emergency room visits and reduced treatment for heart and liver disease.

Scott Dziengelski, president and CEO of the National Association for Behavioral Healthcare, framed the risk differently. He emphasized that methadone is still a Schedule II substance with a narrow margin between a clinically effective dose and a potentially lethal one, and that even modest misdosing can have severe consequences if the medication is improperly dispensed or prescribed. “We’ve balanced risk and reward through the OTP model,” he said, describing an approach he views as effective over 50 years.

Dziengelski’s preferred alternative is to replicate the opioid treatment program model in more places rather than move methadone outside it, through satellite programs and dedicated medication units embedded in hospitals.

Both positions accept that medication works. The disagreement is about whether the supervision, counseling, and monitoring bundled into the clinic model can be preserved when the medication moves to a pharmacy counter.

What This Means for People Seeking Medical Detox

Nothing has changed yet. MOTAA 2.0 is proposed legislation, and until it passes, methadone for opioid use disorder remains available only through certified opioid treatment programs. Buprenorphine, by contrast, can already be prescribed by any clinician with the appropriate DEA registration and filled at a pharmacy.

If you are researching options now, the practical questions are which medications a program offers, whether it provides medically supervised withdrawal management, how take-home dosing is handled, and what counseling is included.

Finding Medical Detox

Search medically supervised detox programs in your area and ask specifically about medication-assisted treatment availability, ASAM level of care, and the transition plan after detox ends. Call 800-996-6135(Sponsored) to find medically supervised detox programs that offer methadone or buprenorphine.